PBMs’ Impact On Drug Prices Probed By House Committee Leaders
Executive Summary
Letter to seven pharmacy benefit managers seeks insight into pros and cons of practices, suggesting that policymakers understand PBMs bring value in lowering costs but that some activities are counterproductive.
You may also be interested in...
Pharmacy “Gag Clause” Bills: Another Simple Fix For Drug Pricing That Is Not So Simple
US Congress wants to prohibit contracts that prevent pharmacists from alerting customers to opportunities to save money by paying out of pocket. Legislation is moving rapidly, but once again, a simple fix to a drug pricing issue may have unintended consequences.
Medicare Part D Plans Can Start Negotiating Indication-Based Pricing This Fall
Policy exempts indications covered by protected classes policy, including cancer treatments.
HHS Advancing Attack On Rebates With Proposal To Revoke Safe Harbor
Upcoming proposed rule could also provide new anti-kickback safe harbor to facilitate value-based contracts, as manufacturers and payers have urged.